Theratechnologies finalized all documentation giving effect to the amendments of some terms and conditions of its credit agreement for which Marathon Asset Management acts as investment manager for certain funds and accounts.
Theratechnologies reached an agreement in principle to amend some of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time, with certain funds and accounts for which Marathon Asset Management, acts as investment manager.
Theratechnologies, a biopharmaceutical company, entered into an agreement with Marathon Asset Management to amend its term loan facility credit agreement to lower the minimum liquidity the company must maintain at any time to $15 million from $20 million.
Theratechnologies drew down on its second tranche of $20 million under its credit agreement dated July 20, 2022, as amended, with certain funds and accounts for which Marathon Asset Management acts as investment manager.
Theratechnologies, a biopharmaceutical company focused on the development and commercialization of innovative therapies, entered into a first amendment to its credit agreement dated July 20, 2022 with certain funds and accounts for which Marathon Asset Management acts as investment manager.
Theratechnologies, a biopharmaceutical company, received funding of $40 million under the terms of its credit agreement with affiliated funds of Marathon Asset Management.
Theratechnologies received a binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management for up to $100 million.